BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23176376)

  • 1. An uninvestigated risk factor for contrast-induced nephropathy in chronic kidney disease: proteinuria.
    Piskinpasa S; Altun B; Akoglu H; Yildirim T; Agbaht K; Yilmaz R; Peynircioglu B; Cil B; Aytemir K; Turgan C
    Ren Fail; 2013; 35(1):62-5. PubMed ID: 23176376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
    Chong E; Shen L; Poh KK; Tan HC
    Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and risk factors of contrast-induced nephropathy after cardiac catheterization in type II diabetic patients: a study among Egyptian patients.
    Sany D; Refaat H; Elshahawy Y; Mohab A; Ezzat H
    Ren Fail; 2014 Mar; 36(2):191-7. PubMed ID: 24138570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease.
    Toprak O; Cirit M; Yesil M; Bayata S; Tanrisev M; Varol U; Ersoy R; Esi E
    Nephrol Dial Transplant; 2007 Mar; 22(3):819-26. PubMed ID: 17090607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
    Shehata M; Hamza M
    Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumour necrosis factor receptors 1 and 2 predict contrast-induced nephropathy and progressive renal dysfunction: a prospective cohort study.
    An JN; Yoo KD; Hwang JH; Kim HL; Kim SH; Yang SH; Kim JH; Kim DK; Oh YK; Kim YS; Lim CS; Lee JP
    Nephrology (Carlton); 2015 Aug; 20(8):552-9. PubMed ID: 25783484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions.
    Li WH; Li DY; Han F; Xu TD; Zhang YB; Zhu H
    Int Urol Nephrol; 2013 Aug; 45(4):1065-70. PubMed ID: 23225080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
    Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
    Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of contrast-induced nephropathy by the serum creatinine level on the day following cardiac catheterization.
    Watanabe M; Saito Y; Aonuma K; Hirayama A; Tamaki N; Tsutsui H; Murohara T; Ogawa H; Akasaka T; Yoshimura M; Sato A; Takayama T; Sakakibara M; Suzuki S; Ishigami K; Onoue K;
    J Cardiol; 2016 Nov; 68(5):412-418. PubMed ID: 26708123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
    Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
    Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
    Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
    Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
    Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
    Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
    Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
    Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
    Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
    Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
    Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
    Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
    Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
    Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of definitions of contrast-induced nephropathy in patients with normal serum creatinine.
    Khatami MR; Nikravan N; Salari-Far M; Davoudi S; Pahlavan-Sabbagh MR
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):94-100. PubMed ID: 26787573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.